The Global Cold Chain Products Market in terms of revenue was estimated to be worth $569 million in 2022 and is poised to reach $711 million by 2027, growing at a CAGR of 4.5% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The market for cold chain products is expanding because of factors like rising zoonotic disease concerns, Rising use of immunoglobulins and other plasma products in a range of therapeutic area and Increasing demand for Plasma-derived medicinal products. The cold chain products industry is anticipated to develop because of the rising demand for plasma freezers and other cold chain products and the technology adoption by advanced cold storage devices. This is also going to attract international investors to that region.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=159802939

Browse in-depth TOC on "Cold Chain Products Market"

92 - Tables
45 - Figures
190 – Pages

Key Market Players:

The prominent players in the global Cold Chain Products Market for Plasma Fractionation are B Medical Systems (US), Blue Star Limited (India), Thermo Fisher Scientific (US), Godrej and Boyce Manufacturing Co. Ltd. (India), Haier Biomedical (China), Eppendorf SE (Germany), Avantor, Inc. (US), Biolife Solutions Inc. (US), and Helmer Scientific Inc. (US).

Driver: Rising use of immunoglobulins and other plasma products in a range of therapeutic area

Immunoglobulins (IgG), also known as immune globulin or gamma globulin plays a crucial role in the treatment of primary immunodeficiency and various other conditions. Polyvalent immunoglobulins, prepared from multiple donors, are essential for addressing immunological disorders such as primary and secondary immunodeficiencies. Additionally, high-dose immunoglobulins exhibit immune-modulating effects in neurological, hematological, and dermatological immune diseases. Hyperimmune immunoglobulins with specific antibodies are utilized for preventing or treating infections like tetanus, measles, and rabies, as well as preventing hemolytic diseases in newborns. The demand for plasma fractionation is primarily driven by the clinical utilization of immunoglobulins, which has been steadily increasing and is expected to continue growing. This growing demand for plasma therapeutics, specifically immunoglobulins, in high-income countries can lead to the production of surplus amounts of other therapeutic proteins such as albumin. Consequently, the demand for cold chain products in the plasma fractionation market is projected to rise due to the increased usage of immunoglobulins and other plasma products, requiring storage equipment throughout the manufacturing and application process.

Opportunity: Demand for Plasma Fractionation Centre

The global demand for plasma-derived products is growing at a rate of approximately 7% per year due to increasing prevalence of diseases like hemophilia, immune deficiency disorders, and alpha-I antitrypsin deficiency. The United States, European Union, and China have the highest demand for these products, driven by the high prevalence of such diseases. Other regions, such as India and Africa, also require plasma fractionation centers. India’s large population and high disease prevalence contribute to its demand for plasma-derived products, although the country relies on imports due to low plasma collection rates. Similarly, Africa faces limited availability of these products due to low plasma collection rates, often hindered by infrastructure and resource challenges.

Request Free Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=159802939

"Temperature monitoring devices segment is expected to witness the fastest growth in the forecast period."

The Cold Chain Products for Plasma Fractionation market is categorized into seven types, including Ultra-low temperature freezers, Plasma freezers, Temperature monitoring devices, Plasma contact shock freezers, Blood transport boxes, Ice-lined refrigerators, and Others. Among these categories, the Temperature monitoring devices segment is projected to experience the highest growth rate from 2022 to 2027. Increased research and development investment in medical devices such as medical freezers and refrigerators are additional factors that are anticipated to drive market growth during the forecasted period

"Blood collection centers and blood component providers accounted for the largest share of the Cold Chain Products Market for Plasma Fractionation in 2021."

The Cold Chain Products Market for Plasma Fractionation is categorized into different end users, including Blood collection centers and blood component providers, Hospitals and transfusion centers, Clinical research laboratories, and Others. Among these, the Blood collection centers, and blood component providers segment held the fastest-growing market for cold chain products for plasma fractionation in 2021. This significant market share can be attributed to factors such as the increasing prevalence of diseases like hemophilia, immune deficiency disorders, and liver diseases, as well as the growing aging population.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=159802939

Recent Developments of Cold Chain Products Industry for Plasma Fractionation:

In January 2023, Haier Biomedical (China) acquired Suzhou Kangsheng (China) to incorporate disposable laboratory plastic consumables into its business portfolio and expand smart laboratory application solution scenarios and rapidly expanding its presence into the field of cryopreserving, cell culture, and microbial applications
In March 2023, Blue Star launched a range of deep freezers with extra storage and higher cooling capacity, manufactured at its new world-class manufacturing facility at Wada.
In March 2022, B Medical’s Ultra-Low Freezer U201 received the WHO PQS prequalification. This is the first-ever Ultra-Low Freezer in the world to receive the WHO PQS prequalification.
About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]